Company Profile
AEON Biopharma Stock Price, News & Analysis
- Ticker:
- AEON
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
0.28 USD (-2.59%)
Close
Last updated: August 6, 2026
19.7M USD
Market cap
Why the stock is moving
As of Aug 6, 2026, AEON closed down 2.59% at $0.2825. No new same-company headline was identified in the current news window.
Company overview
Business overview
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology. The investment case centers on whether the company can turn a highly specialized product profile into a durable franchise.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, AEON sits in the specialty therapeutics segment. Its profile is shaped more by product execution and regulatory positioning than by broad pipeline breadth.
Business Model Characteristics
AEON depends on clinical progress, commercialization strategy, and the ability to convert a focused asset base into repeatable revenue. Investors typically watch launch timing, commercial access, and strategic financing decisions.
Position Within the Biotechnology Landscape
AEON sits in a narrow but catalyst-sensitive corner of biotech where a single program can drive most of the valuation. Compared with larger peers, the stock is more exposed to execution risk and inflection-point revaluation.
Future catalysts
The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path. The next checkpoint matters because it tells investors whether the program is still moving on schedule or whether the timeline needs to be reset. A clean outcome also makes it easier to think about the next regulatory or label step instead of just the current filing.
Recent news
- 01
- 02
AEON Biopharma to Present at the Aegis Capital Corp. Virtual Conference 2025
Source: AEON Biopharma
- 03
- 04
AEON Biopharma Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Source: AEON Biopharma
- 05
AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer
Source: AEON Biopharma
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of AEON Biopharma (AEON)?
AEON Biopharma (AEON) most recently closed at 0.28 USD, a -2.59% move versus the previous session.
What is the market cap of AEON Biopharma (AEON)?
AEON Biopharma currently has a market capitalization of 19.7M USD on BioPharmSignal.
What does AEON Biopharma do?
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology. The investment case centers on whether the company can turn a highly specialized product profile into a durable franchise.
On which exchange is AEON stock listed?
AEON Biopharma (AEON) is associated with NASDAQ, United States, Biopharma.
What is ABP-450?
The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path.
Which conditions is AEON Biopharma targeting with ABP-450?
AEON Biopharma is associated with neurology based on its company overview and current catalyst commentary.
How does AEON Biopharma describe recent progress with ABP-450?
The next three months should center on ABP-450 biosimilar development, especially follow-up with the FDA on the analytical package and the next BPD meeting steps that determine whether the program can stay on a clean regulatory path.
What is Biopharma?
AEON Biopharma is a clinical-stage neurotoxin company focused on botulinum toxin-based therapies and the potential to build a differentiated commercial asset in aesthetics and neurology.